Three M Study (Malabsorption, Microbiota, Mini-Gastric Bypass)
- Conditions
- Obesity (Disorder)
- Registration Number
- NCT03412149
- Lead Sponsor
- University of Roma La Sapienza
- Brief Summary
Bariatric surgery represents the best therapeutic option to induce sustainable weight loss and to solve serious comorbidities improving the life-expectancy and the quality of life. Actually the choice of the procedure is based on the surgeon's and patients preference . Mini gastric bypass(MGB) is an emerging procedure offering excellent results in terms of weight loss and comorbidities (mainly metabolic) control. On the other hand, recent data indicated that the gut microbiota may mediate some of the beneficial effects of bariatric surgery and changes in the composition and diversity of the gut microbiota have been observed after RY Gastric Bypass (RYGB) in humans as well as in mice. However, there are no prospective investigations on Gut Microbiota changes after MGB, despite the procedure is described as "malabsorptive" and there are no studies comparing gut microbiota shift and malabsorption entity in humans after RYGB vs MGB. Thereafter prospective data on the incidence of bile reflux esophageal lesions after MGB are lacking.
The aim of the present multicentric prospective comparative study is to evaluate malabsorption and gut microbiota shift after laparoscopic RYGB vs MGB at 1 year.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 90
- BMI 40-55 kg/m2
- Non smokers
- Primary Mini Gastric Bypass or Roux en Y Gastric Bypass without any concomitant surgeries except hiatal hernia repair
- Enrollment in the two study groups will be on the basis of patient choice.
- Smokers
- Different bowel measurement (plus or minus 10%).
- Conversion to open surgery, reoperation
- Helicobacter Pylori positive previous or current
- Free PPI 4 weeks before 6th month (after surgery)
- Corticosteroids, vitamine E, fish oil treatment 2 months before surgery
- Anti or pre- biotics treatment 2 months before surgery
- Chronic gastrointestinal diseases or syndromes
- Previous bariatric surgery (intragastric balloon excluded)
- Previous resective bowel surgery
- Previous pancreatic surgery
- Previous Hepato BilioPancreatic surgery
- Gallbladder gallstones
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Gut Microbiota 0-6-12 Months To evaluate and compare Roux en Y Gastric Bypass vs Mini Gastric Bypass microbiota profile shift 1 year after surgery and its impact on metabolic and nutritional status after surgery.
- Secondary Outcome Measures
Name Time Method Glucagon - like peptide 1 (GLP-1) 0-12 Months To measure GLP-1 plasma level before and 12 months after surgery in MGB vs RYGB patients
Trial Locations
- Locations (1)
ICOT Hospital
🇮🇹Latina, Italy
ICOT Hospital🇮🇹Latina, Italy